May 13, 2024 4:05pm EDT iBio Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update
Mar 27, 2024 7:00am EDT iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases
Nov 01, 2023 8:24am EDT iBio Further Expands Tech Stack with ShieldTx™; Enhances Immuno-Oncology Development Pipeline with Conditionally Activated MUC16xCD3 Bispecific
Oct 10, 2023 8:00am EDT iBio to Highlight Technology for Advancing Discovery of Bispecifics at Festival of Biologics
